Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: Pharmacokinetic model development for phase 2/3 simulation of exposure

Journal of Clinical Pharmacology

Volumn 46, Issue 1, 2006, Pages 37-44

  Paccaly, Anne ^a   Frick, Annke ^b   Rohatagi, Shashank ^a,c   Liu, Jingli ^a   Shukla, Umesh ^a   Rosenburg, Ronald ^b   Hinder, Markus ^b   Jensen, Bradford K ^a  

^a SANOFI   (France)

^b Clinical Pharmacology and Pharmacokinetics ^*

^c JOHNSON AND JOHNSON   (United States)

Author keywords

FXa inhibitor; Model; Otamixaban; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; OTAMIXABAN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INFUSION; DRUG URINE LEVEL; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BIOTRANSFORMATION; CYCLIC N-OXIDES; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRIDINES;

EID: 29644437323     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005281817     Document Type: Article

References (11)

1. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809-1840.
2. Wykrzykowska JJ, Kathiresan S, Jang IK. Clinician update: direct thrombin inhibitors in acute coronary syndromes. J Thromb Thrombolysis. 2003;15:47-57.
3. Dyke CK, Becker RC, Kleiman NS, et al. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002;105:2385-2391.
4. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res. 2003;109:1-11.
5. Kaiser B. DX-9065a Daiichi. Curr Opin Investig Drugs. 2003; 4:1105-1112.
6. Chu V, Brown K, Colussi D, et al. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res. 2001;103:309-324.
7. Rebello SS, Bentley RG, Morgan SR, et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol. 2001;133:1190-1198.
8. Paccaly A, Ozoux M-L, Chu V, et al. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost. In press.
9. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica. 1996;26:887-895.
10. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 2nd ed. Stockholm, Sweden: Apotekarsocieteten; 1997.
11. Paccaly A, Rohatagi S. Prospective dose prediction for FXa inhibitor otamixaban (OTAM) using PK/PD simulations accounting for non-dose proportional plasma exposure. Clin Pharmacol Ther. 2005;77:40.